DDInter856 DDInter604
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding this risk are conflicting. Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thromboembolic events. In its statement, the FDA has mentioned that increased risk of venous thromboembolism with oral contraceptives such as drospirenone exists but remains lower than the risk of this condition during pregnancy and during the postpartum period, and this should be considered when assessing potential risks of hormonal contraceptive use.
Drospirenone {u} (Compound) resembles {v} (Compound) Flurandrenolide
Drospirenone {u} (Compound) resembles {v} (Compound) Progesterone
Drospirenone {u} (Compound) binds {v} (Gene) PTGS2
Drospirenone {u} (Compound) palliates {v} (Disease) polycystic ovary syndrome
Drospirenone {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Drospirenone {u} (Compound) causes {v} (Side Effect) Uterine haemorrhage
Drospirenone (Compound) resembles Flurandrenolide (Compound)
Drospirenone (Compound) resembles Progesterone (Compound)
Drospirenone (Compound) binds PTGS2 (Gene)
Drospirenone (Compound) palliates polycystic ovary syndrome (Disease)
Drospirenone (Compound) is included by Progesterone Congeners (Pharmacologic Class)
Drospirenone (Compound) causes Uterine haemorrhage (Side Effect)